# US 2010/0168147 A1 · Medicinal Compositions Comprising Buprenorphine And Naloxone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168147 A1
- Document ID: US20100168147A1
- Status: Published application
- Kind: A1
- Application number: 12/529,309
- Filed: 2008-02-15
- Published: 2010-07-01
- Earliest claimed: 2007-03-01
- Assignees: Reckitt Benckiser Healthcare (UK) Limited
- Inventors: Christopher Bourne Chapleo; Neil Hyde
- Web page: https://patentgrep.com/patent/US20100168147A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided a composition for the treatment of pain in human patients wherein said composition comprises buprenorphine to naloxone in a ratio by weight of from 2.1:1 to 8:1, the amount of buprenorphine and naloxone being suitable to provide analgesia, the composition being in a transdermal or transmucosal dosage form. Also provided are an associated method and use.

## Claims

### Claim 1

A composition for the treatment of pain in human patients wherein said composition comprises buprenorphine to naloxone in a ratio by weight of from 2.1:1 to 8:1, the amount of buprenorphine and naloxone being suitable to provide analgesia, the composition being in a transdermal or transmucosal dosage form.

### Claim 2 (depends on 1)

A composition as claimed in claim 1, wherein said ratio is from 2.5:1 to 6:1.

### Claim 3 (depends on 1)

A composition as claimed in claim 1, wherein the amount of buprenorphine per dosage unit is from 10 μg to 8 mg.

### Claim 4 (depends on 1)

A composition as claimed in claim 1, wherein the composition is adapted for administration to the oral-nasal cavity.

### Claim 5

A method for the treatment of pain in a human patient, which method comprises transdermal or transmucosal administration to the patient of buprenorphine and naloxone in the ratio by weight of buprenorphine to naloxone in the range of from 2.1:1 to 8:1.

### Claim 6 (depends on 5)

A method as claimed in claim 5, comprising sublingual administration.

### Claim 7

The use of buprenorphine and naloxone in the manufacture of a medicament for the treatment of pain in a human patient, wherein the medicament is for transdermal or transmucosal administration and the buprenorphine and naloxone are provided in the medicament in a buprenorphine to naloxone ratio by weight of from 2.1:1 to 8:1.

### Claim 8 (depends on 5)

A method as claimed in claim 5, wherein the administration lasts a period of from 1 minute to 10 minutes.

### Claim 9 (depends on 5)

A method as claimed in claim 5, wherein the administration of buprenorphine is in the range 0.25 μg to 640 μg per kg of body weight per 24 hours.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A composition as claimed in claim 1, wherein said ratio is from 3:1 to 5:1.

### Claim 12 (depends on 1)

A composition as claimed in claim 1, wherein said ratio is from 3.5:1 to 4.5:1.

### Claim 13 (depends on 7)

A use as claimed in claim 7, wherein the administration lasts a period of from 1 minute to 10 minutes.

### Claim 14 (depends on 7)

A use as claimed in claim 7, wherein the administration of buprenorphine is in the range 0.25 μg to 640 μg per kg of body weight per 24 hours.
